Pricing Log in Create free account

bioAffinity Technologies, Inc. (BIAF) vs iSpecimen Inc. (ISPC)

bioAffinity Technologies, Inc. and iSpecimen Inc. are both Diagnostics & Research companies. bioAffinity Technologies, Inc. is the larger, with a market value of $5.1M against $2.6M — 2.0× the size. bioAffinity Technologies, Inc. grew revenue faster over the last twelve months: −23.2% against −92.1%. bioAffinity Technologies, Inc. has the higher net margin (−257.3% vs −2,449.0%) and the lower return on invested capital (−408.7% vs 0.00%). Across the 18 metrics below, bioAffinity Technologies, Inc. leads on 11 and iSpecimen Inc. on 7.

Valuation

Metric BIAF ISPC Diagnostics & Research median
P/E n/m n/m 35.56
P/S 0.22 2.75 4.37
P/B 0.35 0.74 3.06
Price to free cash flow n/m n/m 35.76
EV/EBITDA 0.05 0.06 24.35
EV/Sales (0.10) (1.11) 5.51
Earnings yield (2,934.19%) (6,134.78%) (1.89%)
Free cash flow yield (889.05%) (846.31%) (0.15%)

Profitability

Metric BIAF ISPC Diagnostics & Research median
Gross margin 34.61% (108.26%) 50.89%
Operating margin (209.82%) (2,020.05%) (8.57%)
Net margin (257.33%) (2,449.02%) (6.37%)
Free cash flow margin (195.90%) (1,866.61%) 0.00%
Return on equity (1,860.15%) (968.44%) (2.92%)
Return on assets (245.51%) (170.09%) (6.71%)
Return on invested capital (408.67%) 0.00% 0.00%

Growth

Metric BIAF ISPC Diagnostics & Research median
Revenue growth (TTM) (23.18%) (92.11%) 7.69%
EPS growth (last fiscal year) 61.55% 87.03% 25.92%
Revenue growth, 5-year CAGR — (25.10%) 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BIAF ISPC Diagnostics & Research median
Debt to equity 0.15 0.00 0.11
Current ratio 1.44 0.82 2.02
Net debt to EBITDA 0.57 0.95 0.70

Dividend

Metric BIAF ISPC Diagnostics & Research median
Dividend yield — — 0.66%
Payout ratio — — 0.20

Size

Metric BIAF ISPC Diagnostics & Research median
Market cap 5.08m 2.60m 2.16b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack